That's a real good question! Plus I have to give credit to current management in that they genuinely appear to want to help patients. So not only a company that could afford a buyout, but also one with the same commitment to treating/curing.
But once a company is on the map, it's a whole different ball game.
News 
Market Data 
Discover 
AI
